- Atossa Therapeutics is defying the biotech bear market - shares are up ~400% across the past 6 months.
- The company has an opportunity in breast cancer therapy with Endoxifen - a metabolite of 40-year old therapy Tamoxifen, targeting the prevention, neoadjuvant and treatment settings.
- 2 COVID therapies target newly diagnosed and hospitalised patients and are both expected to enter Phase 2 trials - although not in the US, currently.
- Atossa stock reached a high of $9 in late June and, currently, trades at $5.75.
- Current market cap is ~$700m - I would be hoping for a $1bn valuation target if investing, but the risk/reward does not look quite right and I am staying on the sidelines.
For further details see:
Atossa Therapeutics: Bear Market Defying Biotech Running Out Of Upside